Canada Europe Joint funding initiative
Must include a strong collaboration between at least one research entity (academic or private) in Canada and at least one private entity in Wallonia.
Maximum $750,000 EU in Wallonia and $700,000 in Canada.
- A research agreement must be signed by all research entities involved in the project within 3 months after the funding confirmation.
- Intellectual property generated under this funding program will be managed according to the policies of the financial partners involved.
- A licence option will be granted to the CQDM industrial sponsors (currently Merck and Pfizer and their subsidiaries) for the use of the results for R&D purposes only. The main conditions of the end user license option will be negotiated before the beginning of the project and will take into account pre- existing IP as well as contribution from each party.
- CDQM industrial sponsors will have no rights to commercialize the IP resulting from the project or the pre-existing IP.
Letter of Intent External Deadline
Candidates should submit their letter of intent before January 8th, 2016 by using the form available on the website.
Candidates have until February 8th, 2016 to submit their full application.
Internal Deadline: Please submit a copy of your full application along with a signed OR5 form to the Research Services email address at email@example.com by 4.30 pm on Monday, January 26, 2016. It is not necessary to submit your letter of intent internally.
If College-level review is required, your College will communicate its earlier internal deadlines.
Full Proposal: Please submit a copy of your full application along with a signed OR5 form to the Research Services email address at firstname.lastname@example.org. It is not necessary to submit your letter of intent internally.
For full proposal.
How to Apply
Please see the LOI and proposal information and forms.
Each research proposal must:
- Include strong collaboration between at least one research entity (public or private) in Canada and at least one private entity in Wallonia. In Canada the participation of a private organization is highly encouraged and preferred, but not mandatory, Universities and their hospitals and research centres are eligible.
- Generate clear deliverables with immediate applications in the drug discovery and/or development process of new therapeutics.
- Be highly innovative with a strong and wide potential impact on biopharmaceutical research.